NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis



NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).



Read More


Contact Us

Tel: +44 (0) 1603 626 960

Email: info@uropharma.com

Social Media

  • LinkedIn Social Icon

Linkedin.com/company/uropharma

  • Twitter

Twitter.com/UroPharma

  • Facebook

Facebook.com/bladdercontrol

©2017-2020 UroPharma, Inc. All Rights Reserved